Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YPS345 for prevention of steroid-requiring radiation pneumonitis in primary lung cancer
CTR20212450Phase 2Completed
- Sponsor
- Tianfang Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YPS345 in radiation pneumonitis (RP), pulmonary fibrosis (PF), sponsored by Tianfang Pharmaceutical Co., Ltd.. Started Oct 2021; status: completed.
02
Drugs
YPS345
03
Conditions
radiation pneumonitis (RP)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on CTR20212450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212450.